1. Adamyan L.V., Andreeva E.N., Artymuk N.V., Belotserkovtseva L.D., Bezhenar V.F. Uterine fibroids: diagnosis, treatment and rehabilitation. Clinical guidelines for the patient management. (In Russ.) Moscow. 2015:333-335. Available at: https://stopmyoma.ru/wp-content/uploads/2017/09/%D0%9C%D0%B8%D0%BE%D0%BC%D0%B0.%D0%9F%D1%80%D0%BE%D1%82%D0%BE%D0%BA%D0%BE%D0%BB-%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F-2015.pdf.
2. Donnez J., Vazques F., Tomaszewski J., Nouri K., Bouchard P., Fauser B.C., Barlow D.H., Palacios S., Donnez O., Bestel E., Osterloh I., Loumaye E. Long-term treatment of uterine fibroids with uliprista acetate. Fertility and sterility. 2014;101(6):1565-1573. doi: 10.1016/j.fertnstert.2014.02.008.
3. Saveleva G.M., Sukhikh G.T., Radzinskiy V.E. (ed.) National guideline. Gynecology. М.: GEOTARMedia. 2017. 1063 p. Available at: http://www.rosmedlib.ru/book/ISBN9785970441527.html.
4. Kambolova O.T., L. Balios V., Ivanov I.S., Agnaeva N.Z. Experience of using derivatives of squalene in patients with uterine myoma in perimenopau indoor-age period. Vestnik Rossiyskogo Nauchnogo Tsentra Rentgenoradiologii = Russian Scientific Center of Roentgenoradiology. 2010;(10):4-6. (In Russ.) Available at: http://vestnik.rncrr.ru/vestnik/v10/papers/kamb_v10.htm.
5. Kichigin O.V., Arestova I.M., Zanko Y.V. Risk factors of hysteromyoma development and quality of life of patients operated in connection with hysteromyoma. Okhrana materinstva i detstva = Maternal and Child Health. 2013;2(22):36-41. (In Russ.) Available at: https://elib.vsmu.by/handle/123/5331.